- Home
- BNRG vs OGEN Comparison
BNRG vs OGEN Comparison
Compare BNRG & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNRG
- OGEN
- Stock Information
- Founded
- BNRG 2012
- OGEN 1996
- Country
- BNRG Israel
- OGEN United States
- Employees
- BNRG N/A
- OGEN N/A
- Industry
- BNRG
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- BNRG
- OGEN Health Care
- Exchange
- BNRG Nasdaq
- OGEN Nasdaq
- Market Cap
- BNRG 6.2M
- OGEN 5.4M
- IPO Year
- BNRG 2022
- OGEN N/A
- Fundamental
- Price
- BNRG $1.57
- OGEN $1.29
- Analyst Decision
- BNRG
- OGEN
- Analyst Count
- BNRG 0
- OGEN 0
- Target Price
- BNRG N/A
- OGEN N/A
- AVG Volume (30 Days)
- BNRG 92.0K
- OGEN 206.2K
- Earning Date
- BNRG 09-30-2025
- OGEN 11-11-2025
- Dividend Yield
- BNRG N/A
- OGEN N/A
- EPS Growth
- BNRG N/A
- OGEN N/A
- EPS
- BNRG N/A
- OGEN N/A
- Revenue
- BNRG $387,000.00
- OGEN N/A
- Revenue This Year
- BNRG N/A
- OGEN N/A
- Revenue Next Year
- BNRG N/A
- OGEN N/A
- P/E Ratio
- BNRG N/A
- OGEN N/A
- Revenue Growth
- BNRG 843.90
- OGEN N/A
- 52 Week Low
- BNRG $1.50
- OGEN $1.01
- 52 Week High
- BNRG $15.30
- OGEN $18.90
- Technical
- Relative Strength Index (RSI)
- BNRG 38.25
- OGEN 48.27
- Support Level
- BNRG $1.55
- OGEN $1.26
- Resistance Level
- BNRG $1.75
- OGEN $1.34
- Average True Range (ATR)
- BNRG 0.10
- OGEN 0.07
- MACD
- BNRG -0.01
- OGEN -0.01
- Stochastic Oscillator
- BNRG 5.26
- OGEN 20.00
About BNRG Brenmiller Energy Ltd
Brenmiller Energy Ltd is a technology company that develops, produces, markets, and sells thermal energy storage. The technology of the company allows electrification and decarbonization of the industrial industry sector for integration with renewable energy sources and further reduction of carbon emissions.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.